Want to see AIM full AI Analyst Report?
Top Page
AIM ImmunoTech
(NYSE MKT:AIM)
Select Model
Select Model
Rating:42Neutral
Price Target:
$0.21
▼(-15.20% Downside)
Action:Reiterated
Date:09/14/26
The score is driven primarily by very weak financial performance—minimal revenue, large ongoing losses, and continued negative operating and free cash flow that point to ongoing funding and dilution risk. Technicals add further pressure, with the price below key moving averages and bearish momentum indicators. Corporate actions improve compliance and reduce debt, but largely via equity issuance, which limits the positive impact on the overall score.
Positive Factors
Modest Current Leverage
A relatively small debt balance reduces immediate interest and repayment pressure compared with a heavily leveraged structure. This gives AIM more flexibility to direct scarce resources toward clinical development, although continued losses mean the balance sheet still requires careful management.
Negative Factors
Minimal Commercial Revenue
The very small revenue base and deeply negative gross profit show that AIM has not yet established meaningful commercial economics. Persistent operating and net losses make future performance dependent on successful clinical progress, regulatory outcomes, and eventual product commercialization.
Read all positive and negative factors
Positive Factors
Negative Factors
Modest Current Leverage
A relatively small debt balance reduces immediate interest and repayment pressure compared with a heavily leveraged structure. This gives AIM more flexibility to direct scarce resources toward clinical development, although continued losses mean the balance sheet still requires careful management.
Read all positive factors
AIM ImmunoTech (AIM) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$7.77M
Dividend YieldN/A
Average Volume (3M)8.52M
Price to Earnings (P/E)―
Beta (1Y)0.96
Revenue Growth-21.49%
EPS Growth84.62%
CountryUS
Employees19
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)-3.84
Shares Outstanding37,429,420
10 Day Avg. Volume3,912,036
30 Day Avg. Volume8,515,879
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-0.19
Price to Sales (P/S)20.78
P/FCF Ratio-0.16
Enterprise Value/Market Cap>-0.01
Enterprise Value/Revenue>-0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$4.25Price Target Upside1600.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.79
Revenue Forecast (FY)$61.00K
AIM ImmunoTech Business Overview & Revenue Model
Company Description
AIM ImmunoTech Inc., an immuno-pharmaceutical company based in Ocala, Florida, focuses on discovering and advancing treatments for a diverse array of cancers, viral infections, and immune system disorders across the United States. Its primary drug...
AIM ImmunoTech Earnings Call Summary
Earnings Call Date:Mar 27, 2025
(Q4-2024)
| % Change Since: |
Next Earnings Date:Aug 17, 2027
Earnings Call Sentiment Neutral
The earnings call highlighted significant clinical and strategic advancements, including new studies, leadership expansion, and cost reductions. However, financial challenges were noted, with low cash reserves and a risk of delisting from the stock exchange, which the company is actively working to address.Positive Updates
New Clinical Study with AstraZeneca
AIM ImmunoTech announced plans to conduct a new clinical study evaluating Ampligen in combination with AstraZeneca's intranasal influenza vaccine, FluMist, for influenza, including avian flu.
Negative Updates
Low Cash Reserves
As of December 31, 2024, AIM ImmunoTech had approximately $4 million in cash, cash equivalents, and marketable securities, highlighting potential financial constraints.
Read all updates
Q4-2024 Updates
Positive
Negative
New Clinical Study with AstraZeneca
AIM ImmunoTech announced plans to conduct a new clinical study evaluating Ampligen in combination with AstraZeneca's intranasal influenza vaccine, FluMist, for influenza, including avian flu.
Read all positive updates
Company Guidance
During the AIM ImmunoTech Fourth Quarter and Full Year 2024 Update Conference Call, CEO Thomas Equels provided extensive guidance on the company's progress and future plans. Key clinical updates included the continuation into Phase 2 of the DURIPANC trial evaluating Ampligen with AstraZeneca's Imfinzi for metastatic pancreatic cancer, and the completion of the AMP-518 study on post-COVID conditions. Financial metrics revealed that research and development expenses decreased to $6.2 million from $10.9 million the previous year, while general and administrative expenses fell to $13.7 million from $21.1 million. The company held approximately $4 million in cash and equivalents as of December 31, 2024. Strategic initiatives to maintain NYSE American listing, including a potential reverse stock split, were also discussed. The call concluded with a commitment to advancing Ampligen's potential across several high-need medical areas.AIM ImmunoTech Financial Statement Overview
Summary
Income Statement
9
Very Negative
Balance Sheet
28
Negative
Cash Flow
12
Very Negative
| Breakdown | TTM | Mar 2026 | Dec 2024 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 95.00K | 88.00K | 170.00K | 202.00K | 141.00K | 135.00K |
| Gross Profit | -119.00K | -250.00K | 139.00K | 160.00K | 141.00K | -715.00K |
| EBITDA | -12.95M | -12.94M | -16.49M | -28.72M | -19.19M | -18.29M |
| Net Income | -14.27M | -13.96M | -17.32M | -28.96M | -19.45M | -19.13M |
Balance Sheet | ||||||
| Total Assets | 12.73M | 5.78M | 8.61M | 19.38M | 40.49M | 57.70M |
| Cash, Cash Equivalents and Short-Term Investments | 9.96M | 993.00K | 3.98M | 13.07M | 34.19M | 48.27M |
| Total Debt | 3.92M | 4.90M | 2.94M | 718.00K | 837.00K | 149.00K |
| Total Liabilities | 4.99M | 15.56M | 9.93M | 9.15M | 2.02M | 820.00K |
| Stockholders Equity | 7.74M | -9.78M | -1.32M | 10.23M | 38.47M | 56.88M |
Cash Flow | ||||||
| Free Cash Flow | -7.16M | -11.34M | -14.91M | -21.85M | -16.38M | -14.01M |
| Operating Cash Flow | -7.07M | -10.96M | -14.89M | -21.27M | -16.11M | -13.96M |
| Investing Cash Flow | 52.00K | 1.85M | 4.71M | -832.00K | 10.99M | -631.00K |
| Financing Cash Flow | 17.96M | 10.39M | 6.44M | 485.00K | 80.00K | 8.19M |
AIM ImmunoTech Technical Analysis
Negative
0.25
Price Trends
0.25
Negative
0.33
Negative
0.66
Negative
Market Momentum
-0.01
Positive
36.85
Neutral
22.77
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AIM, the sentiment is Negative. The current price of 0.25 is above the 20-day moving average (MA) of 0.23, above the 50-day MA of 0.25, and below the 200-day MA of 0.66, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 36.85 is Neutral, neither overbought nor oversold. The STOCH value of 22.77 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AIM.
AIM ImmunoTech Risk Analysis
AIM ImmunoTech disclosed 43 risk factors in its most recent earnings report. AIM ImmunoTech reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
AIM ImmunoTech Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
50 Neutral | $46.90M | -1.31 | -166.98% | ― | ― | 55.37% | |
48 Neutral | $12.92M | -0.07 | -443.08% | ― | ― | 75.09% | |
46 Neutral | $6.86M | -0.22 | -126.23% | 0.06% | 12.79% | 37.93% | |
44 Neutral | $29.20M | -0.64 | -202.14% | ― | ― | 73.69% | |
42 Neutral | $7.77M | -0.05 | 952.76% | ― | -21.49% | 84.62% | |
42 Neutral | $2.98M | -0.07 | 89.25% | ― | -22.73% | 53.53% |
* General Sector Average
AIM
AIM ImmunoTech
0.21
-2.64
-92.72%
CVM
Cel-Sci
1.66
-7.33
-81.54%
GTBP
GT Biopharma
7.16
-12.83
-64.19%
BCAB
BioAtla
1.79
-29.49
-94.28%
BOLT
Bolt Biotherapeutics
3.56
-1.78
-33.33%
HOWL
Werewolf Therapeutics
0.97
-0.88
-47.55%
AIM ImmunoTech Corporate Events
Business Operations and StrategyPrivate Placements and FinancingShareholder Meetings
AIM ImmunoTech Executes Debt-Reducing Equity Exchange Agreements
Positive
Sep 14, 2026
From Sept. 8 to Sept. 9, 2026, AIM ImmunoTech entered into two exchange agreements and related partitioned promissory notes with Streeterville Capital LLC, converting about $400,000 of a November 18, 2025 promissory note into 1,749,434 shares of c...
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and ComplianceShareholder Meetings
AIM ImmunoTech Reduces Debt via Equity Exchange Agreements
Neutral
Sep 10, 2026
On September 3 and 4, 2026, AIM ImmunoTech entered into two exchange agreements with Streeterville Capital that partitioned a previously issued November 18, 2025 promissory note and converted about $450,000 of the debt into 1,921,441 shares of com...
Business Operations and StrategyPrivate Placements and Financing
AIM ImmunoTech Extinguishes Debt Through Equity Exchanges
Positive
Sep 4, 2026
Between August 31 and September 3, 2026, AIM ImmunoTech entered into five exchange agreements and related partitioned promissory notes with Streeterville Capital, converting approximately $1.22 million of a February 16, 2024 promissory note into 5...
Business Operations and Strategy
AIM ImmunoTech CEO Urges Biodefense Military Integration
Positive
Aug 11, 2026
On August 11, 2026, AIM ImmunoTech’s CEO Thomas K. Equels authored a sponsored article in online defense outlet Breaking Defense arguing that biodefense should be treated as core military force protection, not just a public health function. ...
Business Operations and StrategyShareholder Meetings
AIM ImmunoTech Expands Manufacturing for Ampligen Clinical Supply
Positive
Aug 6, 2026
On July 31, 2026, AIM ImmunoTech entered into a proposal agreement with Sterling Pharma Solutions to manufacture additional batches of the polynucleotide drug substances PolyI and Poly C12U, along with transferring associated test methods at Sterl...
Business Operations and StrategyPrivate Placements and Financing
AIM ImmunoTech Ends At-The-Market Equity Program
Neutral
Aug 5, 2026
AIM ImmunoTech Inc. terminated its Equity Distribution Agreement with Maxim Group LLC, originally signed on April 1, 2025 and amended on April 10, 2026, effective August 15, 2026. The move ends the company’s ability to sell common stock thro...
Business Operations and StrategyPrivate Placements and FinancingShareholder MeetingsStock Split
AIM ImmunoTech Stockholders Approve Key Equity Proposals
Neutral
Jul 17, 2026
On July 15, 2026, AIM ImmunoTech held a Special Meeting of Stockholders at which approximately 38.5% of the company’s outstanding common shares were represented, satisfying the quorum requirement. Shareholders approved multiple proposals aut...
Delistings and Listing ChangesPrivate Placements and FinancingRegulatory Filings and Compliance
AIM ImmunoTech Regains NYSE American Listing Compliance
Positive
Jun 15, 2026
On June 12, 2026, AIM ImmunoTech regained compliance with NYSE American’s continued listing standards related to stockholders’ equity, as confirmed by NYSE Regulation and disclosed on June 15. The move removes the “.BC” bel...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.